This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
GVAX Pancreatic Vaccine
Drug Names(s): CG2505, GM-CSF allogeneic pancreas cancer vaccine, BioSante Pancreatic Vaccine, GVAX Pancreas
Description: GVAX cancer vaccines are comprised of whole tumor cells that have been genetically modified to secrete granulocyte-macrophage colony stimulating factor (GM-CSF), a hormone that systemically activates the immune system to recognize and destroy cancer cells. The tumor cells are then lethally irradiated for safety. Using whole tumor cells is believed to obviate the need to try and pinpoint the specific antigen which may be the most therapeutically important--information which is currently unknown. GVAX cancer vaccines are administered intradermally (into the skin) on an outpatient basis, and are not patient specific (that is they are not derived from the patient's own tumor cells).
Deal Structure: GVAX Pancreatic Vaccine was originally developed by Cell Genesys.
Cell Genesys and BioSante
In June 2009, BioSante Pharmaceuticals and Cell Genesys announced that they entered into a definitive merger agreement by which the companies will merge in an all-stock transaction, with BioSante as the surviving company. The acquisition was completed in October 2009.
BioSante and Aduro
In April 2011, Aduro BioTech licensed GVAX Pancreas Cancer Vaccine (GVAX Pancreas) from BioSante in exchange for milestone and royalty payments after commercialization.
In February 2013, Aduro announced the acquisition of all GVAX assets from BioSante, including intellectual property and cell lines.
BioSante / ANI
In July 2013, ANI Pharmaceuticals announced the change of its name from BioSante Pharmaceuticals.
Partners: ANI Pharmaceuticals, Inc.
GVAX Pancreatic Vaccine News
Scrip Aduro launching IPO
Additional information available to subscribers only: